Universal CAR-T Cells (REVO-UWD-00B) for Refractory and Relapsed Multiple Myeloma

Summary

This study is a single-arm, investigator-initiated clinical trial. The primary objective is to evaluate the safety and preliminary efficacy of administering universal BCMA CAR-T cells to subjects with refractory and relapsed multiple myeloma. Eligible participants will undergo FC preconditioning after signing an informed consent form, followed by a one-time injection of universal UWD-00B cells to assess its safety and efficacy. Subjects will be hospitalized for a period, and after discharge, they will undergo periodic efficacy assessments and long-term survival follow-up for at least five years.

Timeline

Start

2025-07-01

Primary completion

2027-12-30

Completion

2029-12-30

Drugs

Indications